Moderate TSH suppression may be better for patients with thyroid cancer
the ONA take:
According to a new study published online ahead of print in the journal Thyroid, researchers have found that moderate thyroid-stimulating hormone (TSH) suppression may be as beneficial as high suppression of the hormone responsible for driving thyroid cancer.
Higher TSH levels are associated with higher rates of thyroid cancer recurrence, but extreme suppression of TSH is linked with increased adverse events, such as arrhythmias and osteoporosis.
For the 30-year study, researchers analyzed data from 4,941 patients with thyroid cancer. Results showed that extreme TSH suppression offered no additional survival benefit compared with moderate TSH suppression in patients with high-risk disease. Moreover, researchers found that mild TSH suppression was beneficial for patients with low-risk thyroid cancer.
The findings suggest that further research is warranted to prospectively evaluate extreme TSH suppression versus moderate suppression in patients with high-risk thyroid cancer.
Moderate TSH suppression may be as beneficial as high suppression of the hormone responsible for driving the disease.
- Prehabilitation Program Improves Preoperative Fitness in Patients With Colorectal Cancer
- Acupuncture Improves Postoperative Symptoms in Women Undergoing Surgery for Breast Cancer
- Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas
- Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma
- In HER2+ Breast Cancer, Higher TIL Levels Associated With Improved OS
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness
- New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
- Netupitant/Palonosetron Efficacious for Prevention of N/V in Patients Receiving MEC or HEC
- Costs, Complications Higher for Women Who Undergo Second Surgery After BCS
- Omitting RT in Certain Older Women With Early Breast Cancer is Safe
- Fluorescent Nanoparticles Represent Novel Detection Method of HER2 Expression
- Assessment of Stromal Features in DCIS Requires Robustness
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|